Bayer discusses relevant clinical study results

By Modern Retina Staff Reports
Conference|EURETINA

Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.


Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.

See more EURETINA coverage here

Related Videos
View All
Related Content

Ocuphire announces topline results from ZETA-1 phase 2 trial of APX3330 in diabetic retinopathy

January 26th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Using gene therapy to target Usher Syndrome Type 2A

January 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Coherus BioSciences acquiring exclusive US commercial rights to aflibercept biosimilar

January 23rd 2023

In settlement, Arizona eye surgery network to pay $1 million, end discriminatory policies towards patients with disabilities

January 21st 2023

Ocuphire announces topline results from ZETA-1 phase 2 trial of APX3330 in diabetic retinopathy

January 26th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Using gene therapy to target Usher Syndrome Type 2A

January 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Coherus BioSciences acquiring exclusive US commercial rights to aflibercept biosimilar

January 23rd 2023

In settlement, Arizona eye surgery network to pay $1 million, end discriminatory policies towards patients with disabilities

January 21st 2023

Ocuphire announces topline results from ZETA-1 phase 2 trial of APX3330 in diabetic retinopathy

January 26th 2023

Integrating AI to manage DR in a primary care setting

December 1st 2020

Using gene therapy to target Usher Syndrome Type 2A

January 25th 2023

What to expect from virtual AAO 2020

November 5th 2020

Coherus BioSciences acquiring exclusive US commercial rights to aflibercept biosimilar

January 23rd 2023

In settlement, Arizona eye surgery network to pay $1 million, end discriminatory policies towards patients with disabilities

January 21st 2023
Advertise
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.